Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.
Lee L, Draper B, Chaplin N, Philip B, Chin M, Galas-Filipowicz D, Onuoha S, Thomas S, Baldan V, Bughda R, Maciocia P, Kokalaki E, Neves MP, Patel D, Rodriguez-Justo M, Francis J, Yong K, Pule M. Lee L, et al. Among authors: chin m. Blood. 2018 Feb 15;131(7):746-758. doi: 10.1182/blood-2017-05-781351. Epub 2017 Dec 28. Blood. 2018. PMID: 29284597 Free PMC article.
Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma.
Alrasheed N, Lee L, Ghorani E, Henry JY, Conde L, Chin M, Galas-Filipowicz D, Furness AJS, Chavda SJ, Richards H, De-Silva D, Cohen OC, Patel D, Brooks A, Rodriguez-Justo M, Pule M, Herrero J, Quezada SA, Yong KL. Alrasheed N, et al. Among authors: chin m. Clin Cancer Res. 2020 Jul 1;26(13):3443-3454. doi: 10.1158/1078-0432.CCR-19-1714. Epub 2020 Mar 27. Clin Cancer Res. 2020. PMID: 32220887
Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Lee L, Alrasheed N, Khandelwal G, Fitzsimons E, Richards H, Wilson W, Chavda SJ, Henry J, Conde L, De Massy MR, Chin M, Galas-Filipowicz D, Herrero J, Chain B, Quezada SA, Yong K. Lee L, et al. Among authors: chin m. Front Immunol. 2021 Feb 25;12:618610. doi: 10.3389/fimmu.2021.618610. eCollection 2021. Front Immunol. 2021. PMID: 33717112 Free PMC article.
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D'Sa S, Rabin N, Gale RE, Yong KL. Chin M, et al. Blood Cancer J. 2017 Sep 15;7(9):e610. doi: 10.1038/bcj.2017.76. Blood Cancer J. 2017. PMID: 29016571 Free PMC article. Clinical Trial. No abstract available.
Gray platelet syndrome: proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice.
Guerrero JA, Bennett C, van der Weyden L, McKinney H, Chin M, Nurden P, McIntyre Z, Cambridge EL, Estabel J, Wardle-Jones H, Speak AO, Erber WN, Rendon A, Ouwehand WH, Ghevaert C. Guerrero JA, et al. Among authors: chin m. Blood. 2014 Dec 4;124(24):3624-35. doi: 10.1182/blood-2014-04-566760. Epub 2014 Sep 25. Blood. 2014. PMID: 25258341 Free article.
The impact of a tailored nutrition intervention delivered for the duration of hospitalisation on daily energy delivery for patients with critical illness (INTENT): a phase II randomised controlled trial.
Ridley EJ, Bailey M, Chapman MJ, Chapple LS, Deane AM, Gojanovic M, Higgins AM, Hodgson CL, King VL, Marshall AP, Miller EG, McGuinness SP, Parke RL, Paul E, Udy AA; Australian, New Zealand Intensive Care Society Clinical Trials Group. Ridley EJ, et al. Crit Care. 2025 Jan 6;29(1):8. doi: 10.1186/s13054-024-05189-3. Crit Care. 2025. PMID: 39762887 Free article. Clinical Trial.
1,316 results